Response to PHARMAC on Access to new medicines in New Zealand compared to Australia
Milne, R.; Wonder, M.
New Zealand Medical Journal 124(1347): 91-93
2011
ISSN/ISBN: 0028-8446 PMID: 22237576 Document Number: 652762
Document emailed within 1 workday
Related Documents
Metcalfe, S.; Moodie, P.; McNee, W. 2005: PHARMAC and tobacco control in New Zealand: two licensed funded options are already available New Zealand medical journal 118(1217): U1544; author reply U1544; discussion U1544Orubu, E.Samuel.F.; Okwelogu, C.; Opanuga, O.; Nunn, T.; Tuleu, C. 2016: Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development Health Policy and Planning (): -
Grocott, R.; Metcalfe, S.; Alexander, P.; Werner, R. 2013: Assessing the value for money of pharmaceuticals in new Zealand--PHARMAC's approach to cost-utility analysis New Zealand Medical Journal 126(1378): 60-73
Coghlan, R.; Stephens, P.; Mwale, B.; Siyanga, M. 2018: A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia Malaria Journal 17(1): 444
Garrett, J.; Chen, B.; Taylor, D.Robin. 2009: A survey of respiratory and sleep services in New Zealand undertaken by the Thoracic Society of Australia and New Zealand (TSANZ) New Zealand medical journal 122(1289): 10-23
Barnett, J.R. 1991: Where have all the doctors gone? Changes in the geographic distribution of general practitioners in New Zealand since 1975 (3): New Zealand and foreign medical graduates compared New Zealand Medical Journal 104(918): 358-360
Joshua, I.B.; Passmore, P.R.; Sunderland, B.V. 2016: An evaluation of the Essential Medicines List, Standard Treatment Guidelines and prescribing restrictions, as an integrated strategy to enhance quality, efficacy and safety of and improve access to essential medicines in Papua New Guinea Health Policy and Planning 31(4): 538-546
Baber, W.J.; Neeff, M. 2008: Ciproxin HC eardrops application for funding--and response from PHARMAC New Zealand medical journal 121(1281): 111-2; author reply 112-4
Hill, K.; Ward, P.; Grace, B.S.; Gleadle, J. 2017: Social disparities in the prevalence of diabetes in Australia and in the development of end stage renal disease due to diabetes for Aboriginal and Torres Strait Islanders in Australia and Maori and Pacific Islanders in New Zealand Bmc Public Health 17(1): 802
West, D. 2008: The frequency of medicines advertising on New Zealand television New Zealand Medical Journal 121(1277): 97-98
Campbell, C.ë; Morris, C.; Braund, R. 2016: Medicines information in new Zealand: current services and future potential New Zealand Medical Journal 129(1447): 21-28
Martin, P. 2000: Tuberculosis in new Zealand: why do we have twice as much as Australia? New Zealand Medical Journal 113(1105): 68-69
Lee, E.; Braund, R.; Tordoff, J. 2009: Examining the first year of Medicines use Review services provided by pharmacists in new Zealand: 2008 New Zealand Medical Journal 122(1293): 3566
1980: Legionnaire's disease in New Zealand and Australia New Zealand Medical Journal 91(662): 462
Nicol, D.; Owoeye, O. 2013: Using TRIPS flexibilities to facilitate access to medicines Bulletin of the World Health Organization 91(7): 533-539
Drake, P.M.W.; Thangaraj, H. 2010: Molecular farming, patents and access to medicines Expert Review of Vaccines 9(8): 811-819
Drake, P.M.W.; Thangaraj, H. 2010: Molecular farming, patents and access to medicines Expert Review of Vaccines 9(8): 811-819
Klug, H. 2008: Law, Politics, and Access to Essential Medicines in Developing Countries Politics-Society 36(2): 207-245
Janodia, M.D.; Sreedhar, D.; Ligade, V.S.; Pandey, S.; Udupa, N. 2009: Equitable healthcare and access to affordable medicines in India Indian Journal of Medical Research 129(2): 200
Ahmad, K. 2002: Access denied to essential medicines in developing world Lancet. Infectious Diseases 2(12): 711